Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
9
self-reported 2–10 band
Founded
2019
7 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
2
Grant · Jul 2025 · US$ 647.8K
Company type
Privately Held
self-reported
Legal entity
1 brand → 1 confirmed entity
ARGENICA THERAPEUTICS LIMITED
ABN78637578753
Legal entities
Show as table · Argenica Therapeutics: 1 registry entity
| ARGENICA THERAPEUTICS LIMITED | ABN 78637578753 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Argenica Therapeutics(ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes.
Stroke is the leading cause of death and disability worldwide and the economic costs of treatment and post-stroke care are substantial. With current treatments, 20% of sufferers die and 50% are left permanently disabled. Moreover, the burden of stroke is increasing with an aging population and the ongoing epidemics of cardiovascular disease, diabetes and obesity.
Current treatment options remain limited to restoring blood flow through clot removal by tPA (alteplase) thrombolysis and mechanical thrombectomy. Despite considerable research, there are no marketed drugs capable of protecting the brain from damage following stroke. Therefore, the search for widely applicable and effective neuroprotective drugs for stroke patients remains an urgent unmet need and priority.
Argenica has developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy.
Specifically, Argenica has developed a neuroprotective therapeutic, ARG-007, that
- Slows brain tissue death due to inadequate blood supply
- Preserves brain cells and axons
- Extends the treatment time window for stroke patients
- Is not toxic
- Can be delivered in the field by first responders
The Company also intends to explore the development and commercialisation of cationic arginine-rich peptides in other neural injury conditions such as perinatal hypoxia, traumatic brain injury, spinal cord injury, and in patients undergoing endovascular procedures that carry a risk of dislodging material from a diseased artery or triggering an embolus to lodge in a brain artery and thereby causing a stroke.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AUNedlands, Perth, Western Australia 6009Primary
Grid intelligence Members
Funding
Rounds2
Round typeGrant · non-equity funding
Amount (USD)647,800
Stage rank1
Investors named1
Since last round6 mo
Funding
Show as table · 2 funding rounds
| Rounds | 2 |
|---|---|
| Axis | 2019 to 2026 |
| Grant · 20 Jul 2025 | US$ 647.8K |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Counts only. No names are stored here, and none are served.
FAQ
Which legal entity operates under Argenica Therapeutics?
One Western Australia entity on the ABR. ARGENICA THERAPEUTICS LIMITED (ABN 78 637 578 753), high confidence.
How many people work at Argenica Therapeutics?
The record holds 9 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does Argenica Therapeutics have offices?
One address on record, Australia only. Primary: Nedlands, Perth, Western Australia 6009.
Has Argenica Therapeutics raised funding?
Two rounds. Latest 20 July 2025: grant, US$647,800, investor MTPConnect.
Which companies are listed alongside Argenica Therapeutics?
16 profiles list Argenica Therapeutics as a peer — 92nd percentile in Pharmaceutical Manufacturing. It lists ten peers of its own. Dimerix Limited and Kira Biotech Pty Ltd list it back.